The Stem Cell Revolution: Could Mesenchymal Cells Help Us Age Better?

At Reborne Longevity, we curate not only therapies—but ideas.

We recently hosted an exclusive event at our London townhouse clinic, where invited guests were joined by Matthias Bernow of Cellcolabs, a leading Swedish biotech company at the forefront of stem cell innovation.

The evening offered a rare opportunity to preview their ongoing clinical trial investigating how mesenchymal stem cells (MSCs) may support longevity by targeting key biological processes that drive aging. It was a compelling reminder that the future of health may lie not in managing disease—but in modulating the aging process itself.

Why Mesenchymal Stem Cells Matter

While stem cells are often associated with regenerative medicine, MSCs represent a particularly exciting subset. Originally found in bone marrow, fat tissue, and umbilical cords, MSCs are multipotent—meaning they can differentiate into a range of tissue types (bone, cartilage, fat, muscle). But their real therapeutic power lies elsewhere: in their secretome—the array of bioactive molecules they release.

This “cellular language” allows MSCs to:- Calm chronic inflammation, a root cause of nearly all age-related diseases (from heart disease to Alzheimer’s)- Modulate the immune system, correcting imbalances that contribute to immune decline as we age- Enhance mitochondrial function, the engines of our cells, which deteriorate with time- Promote tissue repair, accelerating healing in muscle, vascular, and neural systems

A recent peer-reviewed study published in Biogerontology (Rudnitsky et al., 2025) reviewed these properties in depth, positioning MSCs and their derivatives as powerful candidates for healthspan extension—not just life extension.

The study also explores the use of exosomes and other MSC-derived products, which may deliver many of the same benefits without requiring live cell implantation. These extracellular vesicles could potentially be used to fine-tune the body’s internal environment—reducing systemic inflammation, repairing vascular linings, or even enhancing neuroplasticity.

Who Are Cellcolabs?

Cellcolabs is a Stockholm-based biotech company solving one of the biggest barriers to stem cell therapy: scalability and quality control. They’ve built one of Europe’s first industrial-scale platforms for producing GMP-grade mesenchymal stem cells, allowing for rigorous consistency in research and future therapeutic use.

Their mission is simple but ambitious: make high-purity MSCs available for real-world clinical applications, including longevity medicine.

At Reborne’s private event, the Cellcolabs CEO gave our members a rare look inside their current trial protocols—discussing how their MSCs are being tested for safety, efficacy, and long-term systemic impact. Guests had the opportunity to engage directly with the science and explore how such therapies could integrate into a future, highly personalised longevity pathway.

Why Reborne Is Watching This Space Closely

At Reborne Longevity, our clinical model is built around systems biology, where root-cause resolution takes priority over symptom suppression. MSC-based therapies offer the possibility of treating the underlying imbalances of aging—from mitochondrial decline and immune dysregulation to vascular wear and tear.

We do not offer stem cell therapies of this kind. However, we are tracking the science carefully, and will only introduce these modalities when the evidence, regulation, and patient safety align with our high clinical standards.

We also believe that our members deserve access to the emerging conversations shaping longevity medicine. By hosting innovators like Cellcolabs, we create opportunities for our community to learn directly from those shaping the future of health.

Looking Ahead

As stem cell research moves from theory to trial to practice, Reborne will continue to act as your informed gateway—ensuring that what’s possible is translated into what’s responsible.

If you’d like to stay informed about upcoming events, or receive updates on stem cell research and how it might one day complement our precision medicine programs, please speak to your Reborne Patient Coordinator.

The future is cellular—and it’s closer than you think.